Fundraising FoxPfizer Ventures — 2026 Investments
4 investments dated 2026 · listed companies and verified rows first · show all
Crossbow Therapeutics develops TCR-mimetic antibody therapies designed to target cancer antigens by mimicking T-cell receptors, with a focus on treating solid tumors and hematologic malignancies.
AI & Machine LearningBiotechMedical DevicesCambridge, US
Alexander Nolte(Executive Officer)inDmitri Wiederschain(Executive Officer)in
BoardAlexandra Cantley(Director)inSakae Asanuma(Director)inBriggs Morrison(Executive Officer, Director, Promoter)inIrena Melnikova(Director)in
Co-investorsLifelinkMPM BioImpactPfizer Venture InvestmentsBiotechnology Value FundMirae Asset Venture InvestmentPolaris Partners+1 more
Flare develops AI-driven systems to manage essential workers—such as drivers, cleaners, security guards, and domestic workers—in emerging markets, vertically integrating its technology platform, worker staffing (via subsidiary Drive-Z), and customer implementation.
AI & Machine LearningFuture of WorkHR TechTokyo, JP
Kazuki Kamiya(CEO)Satoru Ichihara(COO)Shinya Hayashi(CSO)Hidefumi Iwaki(CFO)Tomohiro Sasaki(Executive Officer (Product Development))
Co-investorsANOBAKACARTA VENTURES, Inc.Spiral VenturesAgent CapitalCasdin CapitalInvus+2 more
Flare is a Shopify app that calculates location-specific delivery dates, methods, cut-off times and rates at checkout based on a customer's exact postcode or ZIP code, down to individual zones.
E-commerceLogistics & Supply ChainRetail TechSaaSLondon, GB
Daniel Parekh-Hill(CEO)inAlex Hooper(CTO)in
Co-investorsEntrepreneur FirstAgent CapitalBase10 PartnersCasdin CapitalInovia CapitalInvus+3 more
STORM Therapeutics is a clinical-stage biotechnology company developing small molecule drugs that target RNA modifying enzymes to reprogram cells through RNA biology.
BiotechHealthtechMedical Devices
Co-investorsCambridge Innovation CapitalFast Track InitiativeM VenturesPfizer Venture InvestmentsSeroba Life SciencesTaiho Ventures, LLC+3 more
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.